论文部分内容阅读
1.序言在过去一段时期内有大量新药上市,但这些药物在疗效上并不一定比已知的药物有什么优越性。特别令人注意的是那些非甾体抗风湿病药物和β-受体阻断剂。许多新药的分子结构与其母体相比并无多大的变化,如平喘药中对β-拟交感神经作用药物的性质变化不大,但在出现色甘酸钠之后,性质却发生了明显的变化。在化学治疗的领域中,亦同样如此,通过改变治疗药物的结构,试图增加细胞毒素的选择性和扩大药物的治疗范围。此外,在化疗方案中经调节通常在作用机制上不同的抗肿瘤药物,逐渐改善缓解作用。
1. Preamble A large number of new drugs have been on the market in the past period, but the efficacy of these drugs is not necessarily superior to the known drugs. Of particular note are those non-steroidal antirheumatic drugs and beta-blockers. The molecular structure of many new drugs did not change much from their parent counterparts. For example, antiasthmatic drugs did not change much in the nature of β-sympathomimetic drugs, but their properties changed significantly after the emergence of cromolyn. The same is true in the field of chemotherapy, by altering the structure of the therapeutic drug, attempting to increase the selectivity of the cytotoxin and broaden the therapeutic range of the drug. In addition, anti-tumor drugs, which are usually modulated by mechanisms of action in chemotherapy regimens, progressively improve relief.